Global NGS Market size to exceed USD 15 billion by 2025

NGS Market size is set to exceed USD 15 billion by 2025; according to a new research report by Global Market Insights, Inc.
 

Increasing R&D activities in the field of biotechnology and biopharmaceuticals will positively influence the market growth in analysis time frame. NGS technology enables determination of genetic mutations precisely and rapidly than conventional methods. Third generation sequencing provides a broader spectrum of insights that helps in surveillance of pathogens and virulence. Thus, biotechnology and pharmaceutical companies rely on efficient NGS techniques for carrying research activities that should trigger the next generation sequencing market growth.

 

Request Sample Buy NowInquiry Before Buying

 

Technological advancements in next generation sequencing instruments and consumables will propel its usage in healthcare facilities, thereby favoring market growth over the analysis timeframe. Advanced NGS technology provides smaller sets of data thereby, making it manageable as compared to traditional techniques. Additionally, advanced third generation sequencing techniques offers enhanced speed and scalability during research processes. Furthermore, technologically advanced equipment sophisticates the overall research process by reducing complexities occurring in the experiments. As a result, numerous benefits of technologically advanced NGS techniques will foster NGS market growth. However, high cost of the NGS instruments may hinder industry growth to certain extent.
 

U.S. Next Generation Sequencing Market Size, By Application, 2018 & 2025 (USD Million)
NGS Market

Get more details on this report - Request Free Sample PDF
 

Consumables segment is expected to witness around 20.5% growth over the analysis timeframe owing to its extensive usage in detecting genetic diseases precisely. Manufacturers are taking efforts to introduce innovative consumables that will help researchers to gain accurate results. For instance, in 2019 Qiagen has launched liquid biopsy solutions and NGS panels to support advances in cancer research. Therefore, growing availability of such superior quality consumables that should foster the segmental growth.
 

Clinical research segment of next generation sequencing market was valued more than USD 2 billion in 2018. Considerable segmental growth can be attributed to the emerging biotechnology field and increasing prevalence of chronic diseases. Currently available NGS services enables the scientists to arrive at proper diagnosis. Next generation sequencing instruments possess high precision and have high sensitivity that helps in detecting minutest variance in the genes. Additionally, NGS provides several novel diagnostic methods in molecular diagnostics. For instance, development of NGS technologies enabled the researchers to sequence and analyze entire cancer genome systematically. Pathogen detection is one of the most successful application of NGS technology. Therefore, growing use of NGS technology in diagnosing diseases will foster the segmental growth.
 

Target sequencing segment is anticipated to witness more than 19.5% growth throughout the forecast time frame. Targeted sequencing is an accurate technique for analyzing the specific genes of interest by next generation sequencing. Focused panels consist of set of genes that facilitates process specificity. Moreover, targeted sequencing helps in sequencing prominent genes of interest to high depth that enables recognizing of rare variants. Furthermore, it accurately measures individual’s gene pool that can be used for developing personalized medicines. Above mentioned factors should surge the segmental growth.     
 

Ion semiconductor sequencing segment accounted for over 11% revenue share in 2018 and it will grow substantially in coming years. It is a technologically upgraded method of sequencing DNA based on the detection of hydrogen ions that helps to directly translate chemically encoded information into digital information on a semi-conductor chip. This technology is comparatively simpler, faster and cost-effective than any other technology available that should propel the segment growth.
 

Hospitals segment was valued around USD 1.5 billion in 2018. NGS is broadly implemented in hospital for diagnosing immune disorders, infectious diseases and prenatal diseases. It is also used in therapeutic decision making in case of somatic cancers. Hospitals prefer NGS techniques due to the its ability to deliver clinical diagnosis in less time. Furthermore, NGS method is used in hospitals as epidemiologic tool that can be used to collect latest information and recognition of transmission linkages to prevent infections. Thus, growing adoption of NGS technology in hospitals will foster the segmental growth.
 

Browse key industry insights spread across 218 pages with 152 market data tables & 10 figures & charts from the report, “Next Generation Sequencing Market Size By Product Type (Instruments, Consumables, Services), By Application (Research Application, Clinical Application {Cardiovascular, Reproductive Health, Cancer, Infectious Diseases}), By Type (Whole Genome Sequencing, Exome Sequencing, Targeted Sequencing), By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing), End-user (Academic Institutes & Research Centers,  Hospitals & Clinics, Pharmaceutical & Biotechnology Companies) Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Italy, Spain, Japan, India, China, Australia, South Korea, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE), Application Potential, Competitive Market Share & Forecast, 2019 - 2025” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/next-generation-sequencing-market
 

North America NGS market will experience over 20% growth over the forecast timeframe. Rising prevalence of genetic diseases and cancer in the region will surge demand for next generation sequencing over the forecast period. According to the National Institute of Health (NIH), around 1,735,350 million new cancer cases were diagnosed in the U.S. in 2018. This scenario proves beneficial for industry growth as it increases the demand for next generation sequencing techniques utilized in cancer research.  Additionally, major industry players having strong foothold in North America are focused on developing technologically advanced third generation sequencing products. Therefore, growing availability of technologically advanced NGS products will stimulate the regional growth.
 

Few company players operational in NGS market are 10X Genomics, Thermo Fisher, BGI, Roche, Qiagen, Pac-Bio, PerkinElmer, Oxford Nanopore, Nanostring, Illumina, Bio-Rad and Agilent. NGS market players are implementing strategic initiatives such as product launches, collaborations, geographic expansions, mergers and acquisitions in order to acquire prominent market share and sustain industry competition. For instance, in July 2017, Agilent invested to acquire Powerful next generation sequencing IP Portfolio to deliver complete target solutions to customers. This activity will help Agilent in delivering innovative solutions in market that will exceed company’s revenue.
 

Inquiry Before BuyingRequest Sample
 

Next generation sequencing Market. research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2014 to 2025, for the following segments:

NGS Market., By Product (USD million)

  • Instruments
  • Consumables
  • Services

NGS Market., By Application (USD million)

  • Research Application
  • Clinical Application
    • Cardiovascular
    • Reproductive Health
    • Cancer
    • Infectious Diseases
  • Other applications

NGS Market, By Type (USD million)

  • Whole genome sequencing
  • Exome sequencing
  • Targeted sequencing
  • Others

NGS Market., By Technology (USD million)

  • Sequencing by synthesis
  • Ion semiconductor sequencing
  • Others

NGS Market., By End-use (USD million)

  • Academic institutes & research centers
  • Hospitals & clinics
  • Pharmaceutical & biotechnology companies
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info X